We investigated how reanalysis changed the CSF AD classification based on individual CSF markers and based on the combination of CSF markers with an AD profile being defined as abnormal Aβ1-42 and abnormal t-tau or p-tau. This evidence concerns the gene MAPT and Alzheimer disease.